SOLICITATION NOTICE
B -- Generation of Cell Lines from Primary Multiple Myeloma & MGUS Tumors
- Notice Date
- 8/12/2008
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80171-MM
- Archive Date
- 9/10/2008
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen,, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR) intends to procure on a sole-source basis with BTR Inc., 11300 Corobon Lane, Great Falls, VA 22066 for services regarding the generation of cell lines from primary multiple myeloma and MGUS tumors. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541990 and the business size standard is $7.0M. Period of performance: Performance shall be for two months from date of award. The contractor will provide services to support the study entitled "Generation of Cell Lines from Primary Multiple Myeloma and MGUS Tumors", as part of an inter-agency agreement between the NCI, DHHS and NNMC, Defense Department. The work will include the construction of lentivirus vectors that can express oncogenes and viral genes as protein products that inactivate tumor suppressor genes. These vectors will be transfected into packaging cells that will produce infectious lentiviral particles. Combinations of infectious lentiviral particles will be used to infect primary multiple myeloma tumor cells with the expectation that some combinations of these lentiviral particles will generate permanent myeloma cell lines from tumor cells that otherwise could not be grown as cell lines. The resultant myeloma cell lines would then be compared with the original tumor cells to determine what phenotypic changes have occurred as a result of the transition from in vivo tumor cell to an in vitro cell line. The myeloma cell lines will also be used to assess the value of different therapeutic agents. The contractor must provide uniquely qualified professionals, Research Scientists, to do this work based on the following considerations. First, experience growing primary multiple myeloma tumor cells and multiple myeloma cell lines in tissue culture. Second, knowledge on establishing the conditions for isolating and growing normal B-lymphocytes in tissue culture, and then using combinations of cytokines that enable her to cause these cells to differentiate into normal plasmablasts and plasma cells, which are the normal counterpart of multiple myeloma tumor cells. Third, extensive experience (PhD. and published papers) in the construction and use of lentiviral agents to efficiently introduce exogenous genes into quiescent or minimally proliferating normal and tumor cells. Fourth, experience in lentiviral vectors to express several of the genes that are likely needed to generate cell lines from primary myeloma tumor cells. Fifth, experience developing a number of specialized cell and molecular biological procedures that are necessary to efficiently carry out the proposed experiments. BTR Inc. is the only known source that meets all the requirements described above in order to perform the requested services. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM EST on August 26, 2008. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-80171-MM on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=852c917f8689c6fca1f442f31cd8a837&tab=core&_cview=1)
- Record
- SN01638294-W 20080814/080812225650-852c917f8689c6fca1f442f31cd8a837 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |